1. |
Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev, 2018, 3(3): CD012406.
|
2. |
Lee SC, Son KJ, Han CH, et al. Cardiovascular and cerebrovascular-associated mortality in patients with preceding bronchiectasis exacerbation. Ther Adv Respir Dis, 2022, 16: 17534666221144206.
|
3. |
Chen S, Qiu A, Tao Z, et al. Clinical impact of cardiovascular disease on patients with bronchiectasis. BMC Pulm Med, 2020, 20(1): 101.
|
4. |
Chen CL, Huang Y, Yuan JJ, et al. The roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study. Arch Bronconeumol (Engl Ed), 2020, 56(10): 621-629.
|
5. |
Huang HY, Chung FT, Lin CY, et al. Influence of comorbidities and airway clearance on mortality and outcomes of patients with severe bronchiectasis exacerbations in Taiwan. Front Med (Lausanne), 2022, 8: 812775.
|
6. |
成人支气管扩张症诊治专家共识编写组. 成人支气管扩张症诊治专家共识(2012版). 中华危重症医学杂志(电子版), 2012, 5(5): 20-30.
|
7. |
Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers, 2018, 4(1): 45.
|
8. |
陈璐, 司佳卉, 孙点剑一, 等. 中国成年人生活方式和心血管代谢因素与甲基化年龄加速的相关性分析. 中华流行病学杂志, 2022, 43(7): 1019-1029.
|
9. |
Elsaid N, Saied A, Kandil H, et al. Impact of stress and hypertension on the cerebrovasculature. Front Biosci (Landmark Ed), 2021, 26(12): 1643-1652.
|
10. |
Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev, 2022, 11(11): CD010315.
|
11. |
Müllerová H, Marshall J, Nigris ED, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis, 2022, 16: 17534666221113647.
|
12. |
MT D, Criner GJ, Halpin DMG, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT Trial. J Am Heart Assoc, 2022, 11(18): e024350.
|
13. |
Navaratnam V, Root AA, Douglas I, et al. Cardiovascular outcomes after a respiratory tract infection among adults with non-cystic fibrosis bronchiectasis: a general population-based study. Ann Am Thorac Soc, 2018, 15(3): 315-321.
|
14. |
Liu YL, Huang XY, Chen DB, et al. The detrimental qualitative and quantitative alterations of circulating endothelial progenitor cells in patients with bronchiectasis. Respir Med, 2021, 176: 106270.
|
15. |
Choi H, Yang B, Kim YJ, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities. Sci Rep, 2021, 11(1): 7126.
|
16. |
Oscullo G, Gómez-Olivas JD, Beauperthuy T, et al. Impact and treatment of exacerbations in adults with bronchiectasis. Int J Tuberc Lung Dis, 2022, 26(7): 605-611.
|
17. |
Crisafulli E, Guerrero M, Ielpo A, et al. Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a propensity matched analysis. Sci Rep, 2018, 8(1): 9236.
|
18. |
Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev, 2018, 27(147): 170103.
|
19. |
Isiozor NM, Kunutsor SK, Voutilainen A, et al. Association between ideal cardiovascular health and risk of sudden cardiac death and all-cause mortality among middle-aged men in Finland. Eur J Prev Cardiol, 2021, 28(3): 294-300.
|
20. |
Williams MC, Beek EJRV, Hill AT, et al. Coronary artery calcification on thoracic computed tomography is an independent predictor of mortality in patients with bronchiectasis. J Thorac Imaging, 2021, 36(3): 166-173.
|
21. |
Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med, 2023, S2213-2600(23): 00093-0.
|
22. |
Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Semin Respir Crit Care Med, 2021, 42(4): 499-512.
|
23. |
Choi H, Kim SH, Han K, et al. Association between exercise and risk of cardiovascular diseases in patients with non-cystic fibrosis bronchiectasis. Respir Res, 2022, 23(1): 288.
|